CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more
CENTESSA PHARMACEUTICALS (260) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CENTESSA PHARMACEUTICALS (260) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CENTESSA PHARMACEUTICALS - Net Assets Trend (None–None)
This chart illustrates how CENTESSA PHARMACEUTICALS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CENTESSA PHARMACEUTICALS (None–None)
The table below shows the annual net assets of CENTESSA PHARMACEUTICALS from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CENTESSA PHARMACEUTICALS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CENTESSA PHARMACEUTICALS Competitors by Market Cap
The table below lists competitors of CENTESSA PHARMACEUTICALS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Swatch Group AG Class N
SW:UHRN
|
$1.89 Billion |
|
Guangdong Jia Yuan Technology Co Ltd
SHG:688388
|
$1.89 Billion |
|
Christian Dior SE
PINK:CHDRF
|
$1.89 Billion |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266
|
$1.89 Billion |
|
BELLRING BRANDS DL-01
F:D51
|
$1.89 Billion |
|
Kaiser Aluminum Corporation
NASDAQ:KALU
|
$1.89 Billion |
|
Cia de Distribucion Integral
MC:LOG
|
$1.89 Billion |
|
Fresnillo PLC
PINK:FNLPF
|
$1.88 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CENTESSA PHARMACEUTICALS's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CENTESSA PHARMACEUTICALS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CENTESSA PHARMACEUTICALS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CENTESSA PHARMACEUTICALS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CENTESSA PHARMACEUTICALS (260) | €- | N/A | N/A | $1.89 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |